Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip, +27

New England Journal of Medicine

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Luis Paz‐Ares, Stéphane Champiat, W. Victoria Lai, +22

Journal of Clinical Oncology

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Brian G. Feagan, Julián Panés, Marc Ferrante, +21

˜The œLancet. Gastroenterology & hepatology

Autoimmune DiseaseOpen-label Extension StudyImmunologyGastroenterologyClinical Gastroenterology +3

Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors

Mukul Minocha, Varun Khurana, Bin Qin, +2

International Journal of Pharmaceutics

Neuro-oncologyCo-administration StrategyMedicineM-tor InhibitorsPharmacological Agent +7

Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib

Mukul Minocha, Varun Khurana, Bin Qin, +2

International Journal of Pharmaceutics

Enhanced Brain AccumulationMedicineNeuropharmacologyNeuroprotectionNeuroscience +3

609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

Ben Tran, Lisa G. Horvath, Tanya B. Dorff, +12

Annals of Oncology

Bispecific T-cell EngagerUrologyCancer ImmunosurveillanceMedicineImmunology +6

Novel Dexamethasone-Loaded Nanomicelles for the Intermediate and Posterior Segment Uveitis

Ravi Vaishya, Mitan Gokulgandhi, Sulabh Patel, +2

AAPS PharmSciTech

NanomedicineEngineeringVitreous BodyOphthalmologyNovel Dexamethasone-loaded Nanomicelles +4

Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

Taofeek K. Owonikoko, Stéphane Champiat, Melissa L. Johnson, +17

Journal of Clinical Oncology

ImmunologyInhibitory Notch LigandPharmacotherapyImmunotherapeuticsImmunotherapy +17

Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography–tandem mass spectrometry (LC/MS–MS)

Mukul Minocha, Varun Khurana, Ashim K. Mitra

Journal of Chromatography B

MedicineBioanalysisMass SpectrometryImmunologyBiological Mass Spectrometry +9

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Tanya B. Dorff, Lisa G. Horvath, Karen A. Autio, +25

Clinical Cancer Research